Zobrazeno 1 - 10
of 428
pro vyhledávání: '"P, Orbai"'
Autor:
Ana‐Maria Orbai, David Fiorentino, Jamie Perin, Erika Darrah, Qingyuan Yang, Laura Gutierrez‐Alamillo, Clifton O. Bingham, Michelle Petri, Antony Rosen, Livia Casciola‐Rosen
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 12, Pp 807-819 (2024)
Objective Adaptive immunity mediates psoriatic disease pathogenesis. We aimed to identify novel psoriatic autoantigens and their phenotypic associations in deeply characterized patient cohorts. Methods Sera from psoriatic arthritis (PsA) patients wer
Externí odkaz:
https://doaj.org/article/8d5ec29fda92410cb0eb4da5864aef94
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2859-2868 (2023)
Abstract Introduction The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis. Methods In the phase 3 VOYAGE-1 and -2 studies, at week
Externí odkaz:
https://doaj.org/article/5a5553774912446e94efd1f6ff6c66ad
Autor:
Philip J. Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young, Philip S. Helliwell
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and
Externí odkaz:
https://doaj.org/article/f0a17b04c72145eab9ba293da31833b6
Autor:
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-
Externí odkaz:
https://doaj.org/article/8c6f7873019c4474b1623173fd071db0
Autor:
Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores correspo
Externí odkaz:
https://doaj.org/article/aa2336a6b90d4afeb287bfb5c55eaac9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F. Merola, Luminita Pricop, David A. James, Xuan Zhu, Gregory Ligozio
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD w
Externí odkaz:
https://doaj.org/article/88cfee0faae741c196f42420661bb5fc
Autor:
Laure Gossec, Ana-Maria Orbai, Josef S Smolen, Juan D Cañete, Maarten de Wit, Laura C Coates, Uta Kiltz, Penelope Palominos, Rossana Scrivo, Andra Balanescu, Martin Soubrier, Lihi Eder, Umut Kalyoncu, Emanuelle Dernis, Ying Ying Leung, Sandra Meisalu
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Objectives We aimed to evaluate whether obese patients with psoriatic arthritis (PsA) were less likely to be in remission/low disease activity (LDA).Methods We used data from the ReFlaP, an international multi-centre cohort study (NCT03119805), which
Externí odkaz:
https://doaj.org/article/b95f38d6eda64d57a56bd953230e4f5c
Autor:
Ana-Maria Orbai, Philip J. Mease, Philip S. Helliwell, Oliver FitzGerald, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-12 (2022)
Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the i
Externí odkaz:
https://doaj.org/article/fd02bbe68645406c8131109f93801616
Publikováno v:
Journal of Rheumatology; 2024 Supplement, Vol. 51, p80-83, 4p